Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial

随机对照试验 认知行为疗法 失眠的认知行为疗法 失眠症 物理疗法 医学 认知 物理医学与康复 临床心理学 探索性研究 认知疗法 心理学 数字健康 心理治疗师 第N部分,共1次审判 慢性失眠 行为疗法 探索性分析
作者
Eiji Shimizu,Daisuke Sato,Mirai Miyoshi,Haruna Ebisu,Kohei Takahashi,Yosuke Inaba,Yuichi Inoue,Masumi Osao,Masahiro Takeshima,Masaya Ogasawara,Yoshiyuki Hirano,Hideki Hanaoka
出处
期刊:Sleep Medicine [Elsevier BV]
卷期号:148: 109222-109222
标识
DOI:10.1016/j.sleep.2026.109222
摘要

OBJECTIVE: To evaluate the efficacy and safety of a novel, concise 5-week digital cognitive behavioral therapy for insomnia (dCBT-I) application, "IIIP MED: Sleepy Med," compared to zolpidem. METHODS: This exploratory randomized controlled trial enrolled patients with chronic sleep-onset insomnia who remained symptomatic after a 4-week screening period following sleep hygiene education. Participants were randomized to either the fully unguided dCBT-I group or the zolpidem (5 mg/day) group for a 5-week treatment period, followed by a 5-week follow-up. The primary outcome was the change in subjective Sleep Onset Latency (sSOL) from baseline at Week 5. Secondary outcomes included objective sleep parameters via portable electroencephalography (EEG) and safety assessments. RESULTS: At Week 5, the mean sSOL change was -20.65 min (95% CI: [-32.05, -9.65]) in the dCBT-I group (n = 11) and -22.42 min (95% CI: [-29.37, -15.46]) in the zolpidem group (n = 13), with no significant difference between groups (p = 0.7729). At the Week 10 follow-up, the dCBT-I group (n = 9) demonstrated sustained improvement (-29.02 min, 95% CI: [-51.49, -6.54]), whereas the zolpidem group (n = 12) showed a slight recurrence of symptoms (-16.19 min, 95% CI: [-27.08, -5.31], p = 0.2634). The dCBT-I group showed significantly greater improvement in Dysfunctional Beliefs and Attitudes about Sleep at Week 10. No treatment-related adverse events occurred in the dCBT-I group, while one case of daytime somnolence was reported in the zolpidem group. CONCLUSION: The dCBT-I application was associated with an improvement in sSOL over 5 weeks, with no statistically significant between-group difference compared with zolpidem. Furthermore, the improvement in the dCBT-I group was maintained during the 5-week post-treatment follow-up. Given the exploratory design and small sample size (N = 24), the study was underpowered, and these findings should be interpreted with caution. Larger adequately powered confirmatory trials are warranted. TRIAL REGISTRATION: jRCT2032230353.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻哈哈发布了新的文献求助210
刚刚
zzk发布了新的文献求助10
刚刚
11发布了新的文献求助10
1秒前
彭于晏的应助被saiki采纳,获得10
1秒前
2秒前
2秒前
踏实的曲奇完成签到,获得积分10
2秒前
3秒前
mtt完成签到,获得积分10
3秒前
abandon发布了新的文献求助10
4秒前
多啦a萌完成签到,获得积分20
5秒前
5秒前
wjsbhsn完成签到,获得积分20
6秒前
lisa完成签到,获得积分10
6秒前
玫瑰发布了新的文献求助20
6秒前
多啦a萌发布了新的文献求助10
7秒前
这里有妖气完成签到,获得积分10
7秒前
风飒飒完成签到 ,获得积分10
8秒前
张婷完成签到,获得积分10
8秒前
乎乎发布了新的文献求助30
8秒前
草莓软糖发布了新的文献求助10
9秒前
xiaoguoxiaoguo完成签到,获得积分10
9秒前
abandon完成签到,获得积分10
9秒前
9秒前
华仔的应助被Happyocean采纳,获得10
10秒前
在水一方的应助被辛勤电源采纳,获得30
10秒前
11秒前
11秒前
王建强完成签到,获得积分20
11秒前
11秒前
12秒前
正直的冰棍完成签到,获得积分10
13秒前
13秒前
嘻嘻哈哈的应助被听话的馒头采纳,获得10
13秒前
13秒前
Willing发布了新的文献求助50
13秒前
13秒前
研狗发布了新的文献求助10
13秒前
14秒前
大家觉得完成签到,获得积分20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148